Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OvaVAx

Financiado

100 Bacteria free eggs for use in production of human and animal vaccines

Disruptive technology for improved quality and viral yield in egg-based vaccine production and other biotechnology applications. Ovagen Group Ltd. (OGL) is an innovation-based biotechnology company, led by serial entrepreneurs, pr... ver más

30/11/2021

Ovagen

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

OVAGEN GROUP LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 70% 100%

2 Participantes

Ovagen

2.36M€ | Lider

IADA

244.97K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 30 meses Fecha Inicio: 2019-05-23
Fecha Fin: 2021-11-30

Líder del proyecto

OVAGEN GROUP LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Disruptive technology for improved quality and viral yield in egg-based vaccine production and other biotechnology applications. Ovagen Group Ltd. (OGL) is an innovation-based biotechnology company, led by serial entrepreneurs, providing specialist contract services to Biopharma, Pharmaceutical and Vaccine industries. OGL specialises in avian Germ-Free (GF) technology and avian transgenics to Good Manufacturing Practice standards. The company’s vision is to be the go-to supplier of superior quality GF eggs to the vaccine industry globally by 2021. INNOVATION: The founders Dr Leonard Moran CEO and Dr Catherine Caulfield COO together with external VC investors and Enterprise Ireland have invested €12.91M in seven years of R&D, utilising the considerable skills, expertise and experience of our team within this field to develop a unique and novel, patent protected process to enable commercially viable production of the World’s first germ-free (GF) eggs, to eliminate bacterial contamination through eggs for vaccine development and production. This will result in improved quality, production costs and viral yields for vaccine manufacturers leading to cost and availability benefits for health service providers for immunisation programmes to protect the health and lives of populations whilst enabling a rapid response to Global pandemic demands. There is exceptionally strong market pull for our innovative disruptive technology, and the increasing use of vaccines to support global demand for quality eggs estimated CAGR of 8.8% and market value of USD 1.89Bn by 2022. OPPORTUNITY: Over 1bn fertilised specific pathogen free (SPF) chicken eggs are used annually in vaccine manufacture, servicing a vaccine market size estimated to be worth €48bn by 2021 with an AGR of 8.3%.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores